A previous meta-analysis has shown that the circulating apelin level is a prominent athero-protective marker against the development of CAD, while the APLNR rs9943582 polymorphism in the APLNR promoter, is associated with an increased risk of CAD (Chen et al., 2017). This evidence concerns the gene APLN and coronary artery disorder.